

**9th Early Detection Research Network (EDRN) Scientific Workshop**  
**September 8-10, 2014**  
**“Biomarkers at a Crossroad in Personalized Cancer Risk Assessment and Detection”**  
**Hyatt Regency Bethesda**  
**Bethesda, Maryland**

**Breast and Gynecological Cancers Collaborative Group Meeting**

**Tuesday, September 9, 2014**  
**8:00 a.m. – 12:00 p.m.**  
**Haverford Suite**

**Chair:**

Steven Skates, Ph.D., Massachusetts General Hospital

**NCI Program Director:**

Christos Patriotis, Ph.D., National Cancer Institute

**Agenda**

8:00 a.m. – 8:05 a.m.	<u>Welcome</u> Steven Skates, Ph.D., Massachusetts General Hospital
<b>8:05 a.m. – 10:10 a.m.</b>	<b>Breast Cancer</b>
8:05 a.m. – 8:25 a.m.	<u>A Joint Analysis of Metabolomics and Genetics of Breast Cancer</u> Jeffrey Marks, Ph.D., Duke University
8:25 a.m. – 8:30 a.m.	Discussion
8:30 a.m. – 8:50 a.m.	<u>Autoantibody Biomarkers in Basal-like Breast Cancer</u> Joshua LaBaer, M.D., Ph.D., Biodesign Institute/Arizona State University
8:50 a.m. – 8:55 a.m.	Discussion
8:55 a.m. – 9:15 a.m.	<u>Preliminary Validation of Plasma Protein Biomarkers for ER+/PR+ Ductal Breast Cancer</u> Matthew Buas, Ph.D., Fred Hutchinson Cancer Research Center
9:15 a.m. – 9:20 a.m.	Discussion
9:20 a.m. – 9:40 a.m.	<u>Validation of Markers of Progression of Benign Breast Disease</u> Jeffrey Marks, Ph.D., Duke University
9:40 a.m. – 9:45 a.m.	Discussion
9:45 a.m. – 10:05 a.m.	<u>Gene Expression Profiling to Identify Novel Biomarkers that Predict Risk of Recurrence among Breast Cancer Patients</u> Christopher Li, M.D., M.P.H., Ph.D., Fred Hutchinson Cancer Research Center
10:05 a.m. – 10:10 a.m.	Discussion
<b>10:10 a.m. – 10:20 a.m.</b>	<b>Break</b>

**9th Early Detection Research Network (EDRN) Scientific Workshop**  
**September 8-10, 2014**  
**“Biomarkers at a Crossroad in Personalized Cancer Risk Assessment and Detection”**  
**Hyatt Regency Bethesda**  
**Bethesda, Maryland**

**Breast and Gynecological Cancers Collaborative Group Meeting**

<b>10:20 a.m. – 12:00 p.m.</b>	<b>Ovarian Cancer</b>
10:20 a.m. – 10:40 a.m.	<u>TIF Biospecimens and iTRAQ Analyses for Ovarian Cancer Biomarker Discovery</u> Ronny Drapkin, M.D., Ph.D., Dana Farber Cancer Institute
10:40 a.m. – 10:45 a.m.	Discussion
10:45 a.m. – 11:05 a.m.	<u>Integrating Multiple Biospecimen Types, 'Omics' Techniques, and Hierarchical Modeling for Ovarian Cancer Biomarker Discovery</u> Steven Skates, Ph.D., Massachusetts General Hospital
11:05 a.m. – 11:10 a.m.	Discussion
11:10 a.m. – 11:30 a.m.	<u>An Autoantibody Signature for the Early Detection of Ovarian Cancer</u> Karen Anderson, M.D., Ph.D., Arizona State University
11:30 a.m. – 11:35 a.m.	Discussion
11:35 a.m. – 11:55 a.m.	<u>Integrating High-Throughput Technologies for the Identification and Validation of Ovarian Cancer Biomarkers</u> Felix Leung, B.Sc., Mount Sinai Hospital
11:55 a.m. -12:00 p.m.	Discussion
<b>12:00 p.m.</b>	<b>Adjourn</b>